Beatrice M Dias, MD in Litchfield, CT - Dermatology

Beatrice M Dias, MD is a Dermatology physician based in Litchfield, Connecticut. Beatrice M Dias is licensed to practice in Connecticut (license number 044520) and her current practice location is 409 Bantam Rd # A-2, Litchfield, Connecticut. She can be reached at her office (for appointments etc.) via phone at (860) 361-9660.

NPI number for Beatrice M Dias is 1326009473 and her current mailing address is 409 Bantam Rd # A-2, Litchfield, Connecticut. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1326009473.

Contact Information

	Beatrice M Dias, MD
	409 Bantam Rd # A-2, Litchfield, CT 06759-3200
	(860) 361-9660
	(860) 361-9659

Physician's Profile

Full Name	Beatrice M Dias
Gender	Female
Speciality	Dermatology
Location	409 Bantam Rd # A-2, Litchfield, Connecticut
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1326009473
Provider Enumeration Date: 03/29/2006
Last Update Date: 06/30/2008

Medical Identifiers

Medical identifiers for Beatrice M Dias such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1326009473	NPI	-	NPPES
044520	Other	CT	CT LICENSE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207N00000X	Dermatology	044520 (Connecticut)	Primary
207N00000X	Dermatology	189168 (New York)	Secondary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Beatrice M Dias is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Beatrice M Dias, MD 409 Bantam Rd # A-2, Litchfield, CT 06759-3200 Ph: (917) 494-5777	Beatrice M Dias, MD 409 Bantam Rd # A-2, Litchfield, CT 06759-3200 Ph: (860) 361-9660

News Archive

HSS researchers study outcomes of novel implant in patients undergoing wrist fracture surgery

Researchers at Hospital for Special Surgery have launched a study to determine if a novel implant allowing for less invasive surgery for a broken wrist leads to a quicker recovery, less post-operative pain and fewer complications compared to conventional surgical treatment.

Few retail health clinics located in low-income areas, study finds

Most retail health clinics are located in more affluent areas of the U.S., rather than in low-income, medically underserved neighborhoods, according to a study published on Monday in the Archives of Internal Medicine, the AP/Washington Times reports.

Study helps surgeons identify the best individual approach to treat broken hips

Robert Zura, MD, Professor and Robert D'Ambrosia Chair of Orthopaedics at LSU Health New Orleans School of Medicine, was part of an international collaborative study group whose findings will help orthopaedic surgeons identify the best individual approach to treat broken hips in those over age 50.

State News: Ga. Senate oks insurance mandates bill; Va. Assembly says abortion clinics should be regulated as hospitals

State agencies, county prosecutors, insurance companies, and health care employers and associations are mandatory reporters — they're required to report potentially dangerous and unprofessional doctors to medical regulators, who can bar the doctors from practicing and keep patients out of harm's way. But the mandatory reporters sound few alarms, and when they do, regulators rarely take action, the Tribune found.

Financial Times examines legal disputes in India over pharmaceutical patent laws

The Financial Times reports on a legal dispute between the Indian government and the German pharmaceutical group Bayer, writing, "Bayer is appealing against the Indian patent controller's decision in March to override the company's monopoly on its cancer drug Nexavar, and to allow an Indian company to produce and sell the life-extending drug for just $173 a month - one-sixth of the $5,500 a month price charged by Bayer."

Beatrice M Dias, MD - Dermatology in Litchfield, CT